ACEL Power and Iconic Zero-Emission Vessel "Porrima P111" Partner for Landmark International Launch
VANCOUVER, British Columbia, May 27, 2025--(BUSINESS WIRE)--ACEL Power Inc., a Canadian leader in intelligent electric propulsion systems, is proud to announce its participation in the relaunch of Porrima P111—the world's first zero-carbon vessel to circumnavigate the globe without fossil fuels. This collaboration marks the first phase of an ongoing partnership with Porrima to scale intelligent electric systems for auxiliary and main propulsion in future vessels.
Originally built in Switzerland and launched in 2010, Porrima made history by completing four global tours powered entirely by renewable energy. After arriving in Taiwan in 2023, the vessel has undergone more than a year of advanced retrofitting in southern Taiwan. The upgraded ship, now named Porrima P111, stands as a symbol of global collaboration in marine innovation and sustainability.
The official launching ceremony took place on May 22, 2025, at Xingda Port, Kaohsiung City. Hosted by the Co-Founder of Porrima Stan Shih, the event was attended by Taiwan's Minister of Foreign Affairs Lin Chia-lung, Palau President Surangel Whipps Jr. and First Lady Valerie Whipps, highlighting growing diplomatic and environmental cooperation in the Pacific region. The presence of Pacific leaders reflects the growing alignment between technology, sustainability, and diplomacy — a vision ACEL Power supports as we expand into Asia-Pacific markets.
As part of this groundbreaking partnership, ACEL Power is collaborating with Porrima to deliver its Intelligent Electric Series for the vessel's Rigid Inflatable Boat (RIB) tender, utilizing its 50HP system with 40Kwh Battery pack. More than electrification, this integration represents a leap towards intelligent marine mobility — combining zero-emission performance with digitalization. Together, ACEL and Porrima are setting a new global benchmark for sustainable, smart marine innovation. By contributing to this flagship project, ACEL Power is proud to join a global ecosystem of innovators committed to redefining the future of maritime mobility.
Porrima was co-founded by Acer Group founder Stan Shih and "Blue Economy" author Gunter Pauli, with a vision to position net-zero marine innovation as a pillar of future industry. The vessel's retrofit was led by a cross-industry collaboration driven by Shih, leveraging Taiwan's industrial capabilities to build a new zero-carbon marine supply chain.
"This moment marks both a celebration of the past and a bold step into the future," said Anthony Liu, CEO of ACEL Power. "We're honored to power part of Porrima's journey and excited to expand access to electric propulsion through our partnership with VIVIC."
About ACEL Power
ACEL Power, headquartered in Vancouver, Canada, is a pioneering manufacturer of electric outboard propulsion systems, leading the marine industry in innovation and sustainability. Noted for introducing the world's first mass-produced 50 and 75HP electric motors, ACEL Power is committed to shaping a sustainable future through the creation of a smart electric eco-system. With a forward-looking vision, ACEL aims to offer a comprehensive range from 1HP to 650HP, establishing new benchmarks for marine propulsion in performance, safety, and longevity. Leveraging patented technology and integrated software solutions, ACEL Power is driving change towards a cleaner, more efficient boating experience.
For more information, visit www.acelpower.com.
Watch ACEL's electric outboard motors in action here
About Porrima P111
Pioneering Zero emission ship
The ship originally designed in 2008 and built in 2010 was the first to circumnavigate the world in 2012 without a drop of oil under the name "PlanetSolar". In 2017, the solar energy system was strengthened with an intelligent kite operated by a robot and hydrogen made from seawater. After sailing the equivalent of four times around the world, Porrima is ready to industrialize these zero emissions ships which are 20% boat and 80% technologies. These ships support sustainable local economic growth and stimulates entrepreneurship for the common good.
For more information, visit www.porrima.com.tw
View source version on businesswire.com: https://www.businesswire.com/news/home/20250527022112/en/
Contacts
Media Inquiries:ACEL Power Inc.Natasha Chawla, VP Sales & MarketingEmail: natasha@acelpower.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
an hour ago
- Bloomberg
Japan Flags Big Cut to Long-End Bond Issuance Before Risky Sale
Japan's larger-than-expected cut to super-long bond issuance has potential to ease some upward pressure on yields just before an auction this week that risks reigniting turmoil in the debt market. The move by the finance ministry may also prove fortuitous in light of the US attack on Iranian nuclear sites over the weekend. The escalating military action adds to the dangers for super-long yields via higher oil prices and inflation, even if the knee-jerk reaction Monday pulls bonds the other way as investors seek havens.
Business Wire
an hour ago
- Business Wire
Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer
BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today announced positive topline results from the STELLAR-303 phase 3 pivotal trial in which zanzalintinib in combination with atezolizumab (Tecentriq ®) demonstrated a statistically significant improvement in overall survival (OS) versus regorafenib in the intent-to-treat (ITT) population of patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). These topline findings are from the final analysis conducted by the Independent Data Monitoring Committee of one of the dual primary endpoints of the STELLAR-303 phase 3 trial. The trial will proceed to the planned final analysis for the other dual primary endpoint of OS in patients without liver metastases (non-liver metastases, NLM). The safety profiles of zanzalintinib in combination with atezolizumab and of regorafenib were generally consistent with what has been previously observed, and no new safety signals were identified. The ITT population consisted of all randomized patients, regardless of the presence of liver metastases. The NLM subgroup consisted of patients who did not have active liver metastases at baseline as determined by investigator assessment. 'The STELLAR-303 results, which showed a survival benefit with the combination of zanzalintinib and atezolizumab versus regorafenib across all randomized patients with previously treated metastatic colorectal cancer, marks an important first milestone for our zanzalintinib pivotal development program,' said Amy Peterson, M.D., Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer, Exelixis. 'We look forward to discussing the findings with regulatory authorities and presenting the detailed results at an upcoming medical conference.' Secondary endpoints of STELLAR-303 include progression-free survival, objective response rate and duration of response in the ITT population and in the NLM subgroup of patients. Exelixis plans to submit detailed results of STELLAR-303 for presentation at an upcoming medical conference. About STELLAR-303 STELLAR-303 (NCT05425940) is a global, multicenter, randomized, phase 3, open-label study that randomized 901 patients 1:1 to either zanzalintinib (100 mg) in combination with atezolizumab or regorafenib. The study includes patients with previously treated non-MSI-high metastatic CRC. The dual primary endpoints of the study are OS in the ITT population and in the NLM subgroup of patients. Presence of liver metastases at baseline for all enrolled patients was determined by investigator assessment. Secondary endpoints include progression-free survival, objective response rate and duration of response in the ITT population and in the NLM subgroup of patients. More information about the trial is available at About Zanzalintinib Zanzalintinib is a third-generation oral tyrosine kinase inhibitor that inhibits the activity of receptor tyrosine kinases implicated in cancer growth and spread, including VEGF receptors, MET, AXL and MER. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis and resistance to multiple therapies, including immune checkpoint inhibitors. With zanzalintinib, Exelixis sought to build upon its extensive experience with the target profile of cabozantinib, the company's flagship medicine, while improving key characteristics, including pharmacokinetic half-life. Zanzalintinib is currently being developed for the treatment of advanced solid tumors, including colorectal cancer, kidney cancer, head and neck cancer and neuroendocrine tumors. Zanzalintinib is an investigational agent that is not approved for any use and is the subject of ongoing clinical trials. About CRC CRC is the third most common cancer and the second leading cause of cancer-related deaths in the U.S. 1 Approximately 154,000 new cases will be diagnosed in the U.S. with around 53,000 expected deaths from the disease in 2025. 1 CRC is most frequently diagnosed among people aged 65-74 and is more common in men and in people of non-Hispanic American Indian/Alaska Native descent. 2 Nearly a quarter of CRC cases are diagnosed at the metastatic stage, at which point the five-year survival rate is just 16.2%. 2 The liver is the most common site for CRC metastasis. Liver metastases significantly impact survival, with a median five-year survival rate of less than 14% when treated with palliative chemotherapy. 3 About Exelixis Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX ® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements, including, without limitation, statements related to: the therapeutic potential of the combination of zanzalintinib in combination with atezolizumab to improve overall survival in patients with metastatic CRC; Exelixis' plans to discuss the trial data from STELLAR-303 with regulatory authorities and to present detailed findings at an upcoming medical conference; and Exelixis' scientific pursuit to create transformational treatments that give more patients hope for the future. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis' current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: the availability of data at the referenced times; complexities and the unpredictability of the regulatory review and approval processes in the U.S. and elsewhere; Exelixis' continuing compliance with applicable legal and regulatory requirements; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating zanzalintinib; Exelixis' dependence on third-party vendors for the development, manufacture and supply of zanzalintinib; Exelixis' ability to protect its intellectual property rights; market competition; changes in economic and business conditions; and other factors affecting Exelixis and its development programs detailed from time to time under the caption 'Risk Factors' in Exelixis' most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exelixis' future filings with the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law. Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks of Exelixis. TECENTRIQ is a registered U.S. trademark of Genentech, a member of the Roche Group. ___________________________ 1 Key Statistics for Colorectal Cancer. ACS website. Available at: Accessed June 2025. 2 Cancer Stat Facts: Colorectal Cancer. SEER website. Available at: Accessed June 2025. 3 Ros J, Salva F, Dopazo C, et al. Liver transplantation in metastatic colorectal cancer: are we ready for it? Br J Cancer. May 2023;128(10):1797-1806.
Time Business News
an hour ago
- Time Business News
The Rise of forex hong kong: Why This Asian Financial Hub Attracts Global Currency Traders
As one of Asia's most dynamic cities, Hong Kong has long stood at the intersection of finance, innovation, and global commerce. Among its many economic pillars, forex hong kong trading has emerged as a key area of growth. With a favorable regulatory environment, access to global liquidity, and advanced technology, Hong Kong continues to evolve into a strategic center for foreign exchange traders around the world. This article explores the factors that make forex hong kong a compelling destination for currency traders and why its influence continues to rise on the global forex map. A Snapshot of the Forex Market Before diving into Hong Kong's role, it's worth noting the scale of the forex market itself. Foreign exchange trading involves the simultaneous buying and selling of currencies. It is the most liquid market globally, with a daily turnover exceeding $7.5 trillion as of 2025. Unlike stock markets, forex trading occurs 24 hours a day, five days a week, across major financial centers including London, New York, Tokyo, and Hong Kong. This 'follow-the-sun' structure allows for round-the-clock trading activity. Why Hong Kong? Hong Kong's unique position in the global financial ecosystem makes it an ideal environment for forex trading. Let's examine the critical factors: 1. Strategic Geographic Location Hong Kong operates in the GMT+8 timezone, making it a critical link between the closing of the U.S. session and the opening of the Asian markets. Traders in forex hong kong benefit from overlapping sessions that increase liquidity and trading opportunities. 2. Free Capital Flow Unlike mainland China, Hong Kong enjoys unrestricted capital movement, which is crucial for active forex traders. This openness allows investors to deposit, withdraw, and convert currencies without excessive regulatory friction. 3. Regulatory Integrity The Securities and Futures Commission (SFC) oversees financial markets in Hong Kong. Its strict but fair regulatory framework enhances the reputation of forex hong kong as a safe and reliable trading environment. 4. Institutional Presence Most major global banks, brokerage firms, and hedge funds operate from Hong Kong. Their presence increases liquidity, fosters competition, and provides retail traders access to institutional-level services. The Most Traded Currency Pairs in Hong Kong Traders in forex hong kong tend to focus on a mix of global majors and Asia-Pacific pairs. Some popular choices include: USD/HKD : Heavily monitored due to the Hong Kong dollar's peg to the U.S. dollar. : Heavily monitored due to the Hong Kong dollar's peg to the U.S. dollar. USD/CNH : Offers access to the offshore Chinese yuan. : Offers access to the offshore Chinese yuan. EUR/USD , GBP/USD , and USD/JPY : Widely traded with tight spreads. , , and : Widely traded with tight spreads. AUD/USD and NZD/USD: Favorable among traders watching Asia-Pacific economic indicators. Regulation and Safety for Traders The SFC enforces strict regulations to maintain the integrity of forex hong kong. All authorized forex brokers must: Be licensed under the Type 3 'leveraged foreign exchange trading' license. Maintain segregated client accounts to protect trader funds. Submit to regular audits and financial disclosures. Adhere to anti-money laundering (AML) policies. This regulatory oversight protects both retail and institutional traders from fraud, ensuring a level playing field. Best Forex Brokers in Hong Kong Several brokers, both local and international, operate in Hong Kong under SFC regulation. Some well-regarded names include: Saxo Markets – Known for deep liquidity and institutional-grade tools. – Known for deep liquidity and institutional-grade tools. IG Markets – Offers user-friendly platforms and reliable trade execution. – Offers user-friendly platforms and reliable trade execution. Interactive Brokers – A favorite among professional traders and high-frequency investors. – A favorite among professional traders and high-frequency investors. FXCM Asia – Tailored services for Hong Kong residents, including Chinese-language support. Always check the broker's license status on the SFC website before opening an account. How to Start Forex Trading in Hong Kong Getting started in forex hong kong doesn't require a massive investment, but it does demand education and risk awareness. Here's a step-by-step outline: Step 1: Learn the Basics Familiarize yourself with forex concepts like pips, leverage, margin, lot size, and spread. Many brokers offer free educational material and demo accounts. Step 2: Choose a Licensed Broker Pick a reputable broker regulated by the SFC. Consider fees, platform features, customer service, and ease of withdrawals. Step 3: Open a Live or Demo Account Start with a demo account to practice. Once confident, transition to a live account with small capital. Step 4: Develop a Trading Strategy Whether it's scalping, swing trading, or algorithmic trading, build a plan with clear entry/exit rules, risk limits, and position sizes. Step 5: Monitor the Market Use tools like economic calendars, price charts, and trading signals to stay informed and make strategic decisions. Challenges Facing Forex Traders in Hong Kong While the forex hong kong market is thriving, it's not without hurdles: 🔺 Volatility Global news, political events, or economic data releases can cause sudden market movements. Traders must always use stop-loss orders to mitigate risk. 🧾 Tax Considerations Forex profits may be considered personal income or capital gains. Though Hong Kong has a low tax regime, traders should keep clear records and consult with tax advisors. 🔍 Broker Scams Though most brokers are safe, unregulated firms operating from abroad may target Hong Kong residents. Avoid 'too good to be true' offers, and always verify credentials. Final Thoughts: Why Choose forex hong kong? Whether you're a beginner looking to understand currency trading or a hedge fund seeking strategic access to Asia, forex hong kong offers an attractive mix of regulation, infrastructure, and global connectivity. Its close proximity to China, commitment to financial freedom, and cutting-edge technology platforms make Hong Kong not just a local hub—but a global force in forex. If you're serious about exploring opportunities in currency trading, start by exploring regulated brokers, learning technical and fundamental skills, and always prioritizing risk management. The future of forex hong kong is bright—and it's open for those ready to trade smart. TIME BUSINESS NEWS
